10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

VAV1 Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP13853c

Specification

VAV1 Antibody (Center) Blocking peptide - Product Information

Primary Accession P15498

VAV1 Antibody (Center) Blocking peptide - Additional Information

Gene ID 7409

Other Names
Proto-oncogene vav, VAV1, VAV

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13853c was selected from the Center region of VAV1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

VAV1 Antibody (Center) Blocking peptide - Protein Information

Name VAV1

Synonyms VAV

Function
Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation.

Tissue Location
Widely expressed in hematopoietic cells but not in other cell types

VAV1 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

VAV1 Antibody (Center) Blocking peptide - Images

VAV1 Antibody (Center) Blocking peptide - Background

The protein encoded by this proto-oncogene is a member ofthe Dbl family of guanine nucleotide exchange factors (GEF) for theRho family of GTP binding proteins. The protein is important inhematopoiesis, playing a role in T-cell and B-cell development andactivation. This particular GEF has been identified as the specificbinding partner of Nef proteins from HIV-1. Coexpression andbinding of these partners initiates profound morphological changes,cytoskeletal rearrangements and the JNK/SAPK signaling cascade,leading to increased levels of viral transcription and replication.

VAV1 Antibody (Center) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Hollmann, A., et al. Hematol Oncol 28(3):142-150(2010)Barda-Saad, M., et al. EMBO J. 29(14):2315-2328(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)Kim, H.S., et al. Immunity 32(2):175-186(2010)